Milestone Pharmaceuticals (MIST) Assets Average (2019 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Assets Average came in at $153.6 million in Q1 2026, up 123.68% YoY from $68.7 million in Q1 2025, and up 52.65% on a QoQ basis from $100.7 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Assets Average (2019 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 8 years of Assets Average data on file, last reported at $153.6 million in Q1 2026.
- Quarterly Assets Average rose 123.68% year-over-year to $153.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.6 million (up 123.68% YoY) and the FY2025 annual result came in at $94.5 million, up 25.43% from the prior year.
- Assets Average improved to $153.6 million in Q1 2026, from $100.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $153.6 million in Q1 2026 to a low of $54.7 million in Q2 2025.
- A 5-year average of $90.5 million and a median of $88.5 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average tumbled 40.99% — and 2026, when it jumped 123.68%.
- Tracing MIST's Assets Average over 5 years: stood at $80.1 million in 2022, then grew by 1.3% to $81.2 million in 2023, then dropped by 2.55% to $79.1 million in 2024, then increased by 27.25% to $100.7 million in 2025, then surged by 52.65% to $153.6 million in 2026.
- The last three Assets Average figures came in at $153.6 million (Q1 2026), $100.7 million (Q4 2025), and $67.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Milestone Pharmaceuticals | 42.70 Mn | -128.80 Mn | - | 187.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187.68 Mn |
| Mar 31, 2026 | 153.65 Mn |
| Dec 31, 2025 | 100.66 Mn |
| Sep 30, 2025 | 67.58 Mn |
| Jun 30, 2025 | 54.65 Mn |
| Mar 31, 2025 | 68.69 Mn |
| Dec 31, 2024 | 79.10 Mn |
| Sep 30, 2024 | 85.97 Mn |
| Jun 30, 2024 | 92.62 Mn |
| Mar 31, 2024 | 85.61 Mn |
| Dec 31, 2023 | 81.17 Mn |
| Sep 30, 2023 | 92.07 Mn |
| Jun 30, 2023 | 104.05 Mn |
| Mar 31, 2023 | 92.78 Mn |
| Dec 31, 2022 | 80.13 Mn |
| Sep 30, 2022 | 88.53 Mn |
| Jun 30, 2022 | 98.55 Mn |
| Mar 31, 2022 | 112.82 Mn |
| Dec 31, 2021 | 126.81 Mn |
| Sep 30, 2021 | 139.64 Mn |